HomeBT3 • FRA
add
Lineage Cell Therapeutics Inc
Previous close
€0.40
Day range
€0.43 - €0.43
Year range
€0.33 - €1.24
Market cap
112.95M USD
Avg Volume
398.00
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 2.87M | 37.36% |
Operating expense | 4.40M | 480.61% |
Net income | -3.27M | 31.46% |
Net profit margin | -114.12 | 50.10% |
Earnings per share | -0.01 | 63.24% |
EBITDA | -4.96M | -86.64% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 47.80M | 34.69% |
Total assets | 113.22M | 12.08% |
Total liabilities | 36.21M | -7.15% |
Total equity | 77.01M | — |
Shares outstanding | 228.36M | — |
Price to book | 1.12 | — |
Return on assets | -12.18% | — |
Return on capital | -17.37% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -3.27M | 31.46% |
Cash from operations | -6.35M | -5.43% |
Cash from investing | 2.64M | -72.95% |
Cash from financing | 21.73M | 167,284.62% |
Net change in cash | 18.05M | 352.10% |
Free cash flow | -3.50M | -594.59% |
About
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Founded
1990
Website
Employees
74
